For patients at low to moderate risk of recurrent VTE who require interruption of VKA therapy for invasive procedures, should periprocedural bridging with LMWH or UHF vs interruption of VKA therapy alone be used? 15. For patients interrupting DOAC therapy for scheduled invasive procedures, should performing laboratory testing for DOAC anticoagulant effect be used vs interrupting DOAC therapy alone? 16. For patients receiving VKA for treatment of VTE with INR of .4.5 but ,10 and without clinically relevant bleeding, should temporary cessation of VKA plus administration of vitamin K vs temporary cessation of VKA alone be used? 17. For patients with life-threatening bleeding during VKA treatment of VTE, should 4-factor PCC vs FFP be used, in addition to cessation of VKA and IV vitamin K? 18. For patients with life-threatening bleeding during oral direct Xa inhibitor treatment of VTE, should cessation of direct Xa inhibitor plus reversal of the direct Xa inhibitor anticoagulant effect vs cessation of direct Xa inhibitor alone be used? 19. For patients with life-threatening bleeding during dabigatran treatment of VTE, should cessation of dabigatran plus idarucizumab administration vs cessation of dabigatran alone be used? 20. For patients with life-threatening bleeding during LMWH or UFH treatment of VTE, should cessation of LMWH or UFH plus protamine vs cessation of LMWH or UFH alone be used? 21. For patients receiving treatment of VTE who survive an episode of anticoagulation therapy-related major bleeding, should resumption of oral anticoagulation therapy vs discontinuation of oral anticoagulation therapy be used? 22. For patients with creatinine clearance of $50 mL/min receiving DOAC therapy for treatment of VTE, should renal function be monitored every 6 to 12 mo vs no such monitoring? 23. 